Research programme: antibody therapeutics - Y-Biologics

Drug Profile

Research programme: antibody therapeutics - Y-Biologics

Alternative Names: AR 001; AR 003; YBL 001; YBL 002; YBL 003; YBL 004; YBL 005; YBL 006; YBL 007

Latest Information Update: 11 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Y-Biologics
  • Developer Ahn-Gook Pharmaceutical; Y-Biologics
  • Class Antibodies; Biobetters; Drug conjugates
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer
  • Research Autoimmune disorders; Multiple sclerosis

Most Recent Events

  • 10 Mar 2017 Research programme: antibody therapeutics - Y-Biologics is available for licensing as of 10 Mar 2017. http://ybiologics.com/eng/technology/pipeline.asp
  • 09 Mar 2017 Early research in Autoimmune disorders in South Korea (Parenteral) before March 2017
  • 09 Mar 2017 Early research in Multiple sclerosis in South Korea (Parenteral) before March 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top